statMed.org is designed to help students of medicine to learn about differential diagnosis.
It is NOT a clinical decision support tool and should NOT be used to guide decisions about clinical practice.
The website should not be used by people who are not studying medicine. If you are not studying medicine please leave the website. statMed.org is for medical educational purposes only and it is not intended to constitute professional medical advice, diagnosis or treatment.
It is NOT a symptom checker.
If you are concerned about a medical problem you should immediately seek medical assistance from a doctor.
statMed.org and it's affiliates, officers and employees shall not be held liable in anyway responsible for any direct or indirect consquences resulting from the use of the website.
Please enter at least one feature (symptom, sign or investigation result) before performing the calculation.
For example, if chest pain and low oxygen saturations were present, but haemoptysis was absent, the features section should look as follows:
To add a feature that is present, start typing and then click the green arrow.
To add the absence of a feature (i.e. a 'negative' finding), start typing then click the red cross.
If you want to remove a feature from the list simply click the grey cross in the box to the right of the feature.
Immune checkpoint inhibitors are a type of immunotherapy that are increasingly being used to treat certain types of cancer, as an alternative to cytotoxic chemotherapy. In contrast to therapies such as chemotherapy and tumour-targeted drugs that directly affect the growth and proliferation of tumour cells, these targeted treatments harness the body’s natural anti-cancer immune response. They boost its ability to attack and destroy the cancer cells.
Mechanism of action
T-cells are an important part of our immune system which help destroy cancer cells. Some cancer cells make high levels of proteins that turn T-cells off. Checkpoint inhibitors block this process and reactivate and increase the body’s own T-cell population, enhancing the immune systems own ability to recognise and fight cancer cells.
Ipilimumab (Yervoy) is a checkpoint inhibitor that blocks CTLA-4 (cytotoxic T lymphocyte-associated protein 4). It is a treatment for advanced melanoma.
Nivolumab (Opdivo) and pembrolizumab (Keytruda) blocks PD-1 (programmed cell death protein 1). These are treatments for melanoma, Hodgkin's lymphoma, non-small cell lung cancer and urological cancers.
Atezolizumab, Avelumab and Durvalumab block PD-L1 and is used to treat lung cancer and urothelial cancer. It is also undergoing trials as a treatment for breast cancer.
The proteins CTLA-4 and PD-1 are found on T-cells and PD-L1 are found on cancer cells.
This mechanism of action of these drugs can result in side effects termed 'Immune-related adverse events' that are inflammatory and autoimmune in nature. This is because all immune cells are boosted by these drugs, not just the ones that target cancer. The over-active T-cells can produce side effects such as:
Dry, itchy skin and rashes (most commonly)
Nausea and vomiting
Tiredness and fatigue
Shortness of breath and a dry cough.
Management of such side effects reflects the inflammatory nature, often involving corticosteroids.
It is important to monitor liver, kidney and thyroid function as these drugs can affect these organs.